Literature DB >> 20731722

Protective efficacy of recombinant urease B and aluminum hydroxide against Helicobacter pylori infection in a mouse model.

Rodolfo E Bégué1, Halina Sadowska-Krowicka.   

Abstract

Efforts are underway for the development of an effective vaccine against Helicobacter pylori infection. We prepared recombinant full-length (568 aa) H. pylori recombinant urease B (rUreB) protein and tested it for immunogenicity and protection. BALB/c mice received either rUreB (40 μg) plus CpG (10 μg) intranasally, rUreB (50 μg) plus 3% aluminum hydroxide (50 μL) intramuscularly or rUreB (25 μg) plus Freund's adjuvant (25 μL) subcutaneously, three times (weeks 0, 2 and 6). Intranasal rUreB plus CpG was neither immunogenic nor protective; intramuscular rUreB plus aluminum hydroxide was immunogenic and modestly protective, and subcutaneous rUreB plus Freund's adjuvant was immunogenic and highly protective. The fact that protection was improved with Freund's adjuvant indicates that rUreB is a good antigen for a vaccine but that it needs a stronger adjuvant than aluminum hydroxide.
© 2010 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20731722      PMCID： PMC2970735          DOI： 10.1111/j.1574-695X.2010.00726.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN： 0928-8244


  27 in total

1.  Immunogenicity of Recombinant Helicobacter pylori Urease B Administered by Various Routes and with Different Adjuvants.

Authors:  Rodolfo E Bégué; Alyson Moll
Journal:  Open Vaccine J       Date:  2009-01-01

2.  Real-time PCR for quantification of Helicobacter felis in mouse stomach.

Authors:  Rodolfo E Bégué; Jennifer Manning; Hernán Correa
Journal:  South Med J       Date:  2006-11       Impact factor: 0.954

3.  Safety of oral immunisation with recombinant urease in patients with Helicobacter pylori infection.

Authors:  C Kreiss; T Buclin; M Cosma; I Corthésy-Theulaz; P Michetti
Journal:  Lancet       Date:  1996-06-08       Impact factor: 79.321

4.  Essential role of urease in pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets.

Authors:  K A Eaton; C L Brooks; D R Morgan; S Krakowka
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

5.  Modulating the adjuvanticity of alum by co-administration of muramyl di-peptide (MDP) or Quil-A.

Authors:  Sterghios A Moschos; Vincent W Bramwell; Satyanarayna Somavarapu; H Oya Alpar
Journal:  Vaccine       Date:  2005-09-19       Impact factor: 3.641

6.  Immunization of rhesus monkeys with a mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori.

Authors:  C K Lee; K Soike; P Giannasca; J Hill; R Weltzin; H Kleanthous; J Blanchard; T P Monath
Journal:  Vaccine       Date:  1999-08-06       Impact factor: 3.641

7.  Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization.

Authors:  S J Czinn; A Cai; J G Nedrud
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

8.  Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease.

Authors:  P Michetti; I Corthésy-Theulaz; C Davin; R Haas; A C Vaney; M Heitz; J Bille; J P Kraehenbuhl; E Saraga; A L Blum
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

9.  Bovine anti-Helicobacter pylori antibodies for oral immunotherapy.

Authors:  T H Casswall; H O Nilsson; L Björck; S Sjöstedt; Li Xu; C K Nord; T Borén; T Wadström; L Hammarström
Journal:  Scand J Gastroenterol       Date:  2002-12       Impact factor: 2.423

10.  Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection.

Authors:  R Weltzin; B Guy; W D Thomas; P J Giannasca; T P Monath
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441
View more
  6 in total

1.  Intranasal immunization with an epitope-based vaccine results in earlier protection, but not better protective efficacy, against Helicobacter pylori compared to subcutaneous immunization.

Authors:  Haibo Li; Jinyong Zhang; Yafei He; Bin Li; Li Chen; Weiwei Huang; Quanming Zou; Chao Wu
Journal:  Immunol Res       Date:  2015-07       Impact factor: 2.829

2.  Inhibition of H. pylori colonization and prevention of gastritis in murine model.

Authors:  Mahdieh Ameri Shah Reza; Seyed Latif Mousavi Gargari; Iraj Rasooli; Mohammadreza Jalali Nadoushan; Walead Ebrahimizadeh
Journal:  World J Microbiol Biotechnol       Date:  2012-04-28       Impact factor: 3.312

3.  GM-CSF is key in the efficacy of vaccine-induced reduction of Helicobacter pylori infection.

Authors:  Laurie Vaillant; Paul Oster; Brynn McMillan; Eulalia Orozco Fernandez; Dominique Velin
Journal:  Helicobacter       Date:  2022-01-29       Impact factor: 5.182

4.  Immunization with the immunodominant Helicobacter suis urease subunit B induces partial protection against H. suis infection in a mouse model.

Authors:  Miet Vermoote; Katleen Van Steendam; Bram Flahou; Annemieke Smet; Frank Pasmans; Pieter Glibert; Richard Ducatelle; Dieter Deforce; Freddy Haesebrouck
Journal:  Vet Res       Date:  2012-10-26       Impact factor: 3.683

5.  Experimental Immunization Based on Plasmodium Antigens Isolated by Antibody Affinity.

Authors:  Ali N Kamali; Patricia Marín-García; Isabel G Azcárate; Antonio Puyet; Amalia Diez; José M Bautista
Journal:  J Immunol Res       Date:  2015-10-11       Impact factor: 4.818

6.  Evaluating the immune responses of mice to subcutaneous immunization with Helicobacter pylori urease B subunit.

Authors:  Peng Sun; Jia-Qi Wang; Yu-Tao Zhang; Sheng-Guo Zhao
Journal:  J Anim Sci Biotechnol       Date:  2014-02-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.